Using life, for life.
We measure what matters to patients, so better medicines reach them sooner.
From devices to decisions.
Usin’Life began in 2010 building medical devices that measured disease directly in patients, producing first-in-class, real-time endpoints in Parkinson’s disease, muscular and myotonic dystrophy, ALS and myasthenia gravis. Our founder then spent a decade bringing digital and biomarker endpoints into clinical trials at Biogen, Pfizer and Verge Genomics.
Since then, the technology has caught up with the idea. Wearables, speech analysis, EEG and AI can now measure how a disease changes daily life, and regulators have begun accepting these measures as trial endpoints.
Today Usin’Life returns to its original mission with Prepoint™, a platform that turns early clinical studies into evidence for the decisions that follow.
Our news archive records blogs since 2010. Read the news archive →
Three convictions.
Measure what patients feel.
A drug that works should show up in how people speak, move and sleep.
Decide early.
The answer to Phase 2 should be found in Phase 1.
Earn trust with evidence.
Every recommendation is traceable, and every prediction is tested.
Leadership
Anil Tarachandani, PhD, Founder
Anil has spent three decades in drug development, leading programs that brought digital and biomarker endpoints into clinical trials at Pfizer, Verge Genomics, Biogen and Merck. He founded Usin’Life to give every drug program that kind of evidence from the very first human study.
Start with one study.
Add Prepoint Measure to the Phase 1 you’re already planning, as an exploratory endpoint — low risk, clear criteria. Your data stays yours.